Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphangioleiomyomatosis.

Simon R Johnson1, Anne E Tattersfield

  • 1Division of Therapeutics, University Hospital, Queens Medical Centre, Nottingham, UK. simon.johnson@nottingham.ac.uk

Seminars in Respiratory and Critical Care Medicine
|August 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring glucocorticoid receptor signalling in lymphangioleiomyomatosis.

ERJ open research·2026
Same author

Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets.

The European respiratory journal·2026
Same author

A statistical model for lung function trajectory and mortality in patients with fibrotic interstitial lung disease.

American journal of respiratory and critical care medicine·2026
Same author

High prevalence of TSC2 mutations in lung tissue samples from patients with sporadic lymphangioleiomyomatosis.

The European respiratory journal·2026
Same author

Assessment of mosaic loss of chromosome Y in pulmonary fibrosis reveals limited association with susceptibility or disease severity.

BMJ open respiratory research·2026
Same author

Prospective study of fibrosis in the lung endpoints (PROFILE): characteristics of an incident cohort of patients with idiopathic pulmonary fibrosis.

BMJ open respiratory research·2026
Same journal

Monographic Issue on New Concepts in Acute Exacerbations of COPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.

Seminars in respiratory and critical care medicine·2026
Same journal

Radiological Approach to Severe Respiratory Infections and Pulmonary Complications in Immunocompromised Patients.

Seminars in respiratory and critical care medicine·2026
Same journal

Two Sides of the Same Smoke: Decoding Respiratory Bronchiolitis-Associated Interstitial Lung Disease and Alveolar Macrophage Pneumonia.

Seminars in respiratory and critical care medicine·2026
Same journal

Role of Vaccination in the Prevention of ECOPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives.

Seminars in respiratory and critical care medicine·2026
See all related articles

Lymphangioleiomyomatosis (LAM) is a rare lung disease caused by abnormal smooth muscle cells. Current treatments focus on managing symptoms as its progression often leads to respiratory failure.

Area of Science:

  • Pulmonary Medicine
  • Oncology
  • Genetics

Background:

  • Lymphangioleiomyomatosis (LAM) is a rare disease characterized by abnormal smooth muscle cell proliferation in the lungs and lymphatics.
  • It affects women in their mid-thirties, with higher prevalence in those with tuberous sclerosis complex (TSC).
  • LAM presents with airflow obstruction, lung cysts, pneumothorax, and chylous collections, leading to progressive respiratory failure.

Purpose of the Study:

  • To describe the characteristics, diagnosis, and current management strategies for Lymphangioleiomyomatosis.
  • To highlight the association between LAM, tuberous sclerosis complex (TSC), and the TSC-2 gene.
  • To discuss the diagnostic utility of LAM cell phenotype and the limitations of current therapeutic interventions.

Main Methods:

Related Experiment Videos

  • Review of existing literature on LAM pathophysiology, clinical presentation, and treatment.
  • Analysis of the genetic basis (TSC-2 gene) and cellular phenotype of LAM cells.
  • Summary of supportive care measures and experimental hormone therapies.

Main Results:

  • LAM cells exhibit an unusual phenotype expressing smooth muscle proteins, melanoma proteins, and hormone receptors, aiding diagnosis.
  • Abnormalities in the TSC-2 gene are implicated in the disordered growth of LAM cells.
  • Current treatments are primarily supportive, addressing complications like airflow obstruction and pneumothorax.

Conclusions:

  • LAM is a progressive disease requiring comprehensive symptom management.
  • Hormone therapies show limited efficacy in rapidly progressing LAM, necessitating further research.
  • Understanding LAM cell characteristics and genetic links is crucial for future therapeutic development.